Bill Ackman Supports Valeant’s Allergan Offer
April 22 (Bloomberg) -- Valeant Pharmaceuticals International offered to buy Allergan in a cash-and-stock deal valued at $45.7 billion that will give the Canadian company the Botox wrinkle treatment. Pershing Square Capital Management LP, the fund run by Bill Ackman, Allergan’s largest shareholder, supports the offer, Valeant said. Stephanie Ruhle reports on Bloomberg Television’s “In The Loop.” (Source: Bloomberg)
Most Recent Videos
Soylent: The Food of the Future?
41:55 - Rob Rhinehart, Soylent's chief executive officer, discusses the company's quest to disrupt the food industry. He speaks with Bloomberg's Emily Chang on "Bloomberg West." (Source: Bloomberg)